In the rapidly shifting landscape of clinical genomics, the journey for patients with undiagnosed rare diseases is often long, expensive, and emotionally taxing. This period of uncertainty, frequently referred to as the "diagnostic odyssey," has become a primary target for researchers looking to integrate high-throughput sequencing into standard clinical workflows. A new study published in Human Genetics and Genomics Advances (HGGA) by Dr. Tamara Roman and her colleagues at NCGENES 2 seeks to determine whether moving exome sequencing (ES) to the earliest stages of outpatient evaluation can provide the answers families have been searching for years to find.
The Diagnostic Odyssey: A Persistent Clinical Challenge
For decades, patients presenting with complex, multi-system disorders have navigated a labyrinth of specialists—from neurologists to immunologists—undergoing a battery of tests that often yield inconclusive results. The diagnostic odyssey is defined not just by its duration, but by the physical, financial, and psychological toll it takes on patients and their families.
The traditional approach to diagnosis has historically been tiered: clinicians start with single-gene tests or broad clinical examinations, only turning to comprehensive genomic tools like exome sequencing when other avenues are exhausted. However, Dr. Tamara Roman, a Variant Analyst at UNC Health, argues that this conventional hierarchy may be counterproductive. Her latest research, "Exome sequencing early in outpatient evaluation in NCGENES 2: Changing the course of the diagnostic odyssey?", posits that integrating ES into the early stages of the outpatient clinical visit could significantly reduce the time to diagnosis and improve patient outcomes.
Chronology of the NCGENES 2 Study
The NCGENES 2 project represents a longitudinal effort to assess the real-world application of genomic medicine. Dr. Roman began her work on this initiative during her postdoctoral fellowship, a time when the field was grappling with the massive influx of data produced by next-generation sequencing technologies.
Phase 1: Identifying the Gap
The project was born out of a realization that variant classification—the process of determining whether a genetic mutation is the cause of a disease—is often the primary bottleneck in clinical utility. Researchers recognized that while technology could produce data quickly, the interpretation of that data remained a hurdle.
Phase 2: Collaborative Implementation
The study was designed as a high-level collaborative effort. Unlike siloed research, the NCGENES 2 team brought together a multidisciplinary task force comprising clinical geneticists, laboratory geneticists, genetic counselors, research faculty, and students. This structure was critical, as it mirrored the reality of the clinical environment where information must flow seamlessly between the lab bench and the patient’s bedside.
Phase 3: Data Analysis and Evaluation
Over the course of the project, the team evaluated the clinical utility and impact of sequencing data across diverse patient cohorts. They focused on how early deployment changed the diagnostic trajectory, specifically measuring how often a definitive answer was reached faster than it would have been under standard care models.
The Role of Variants of Uncertain Significance (VUS)
A central pillar of Dr. Roman’s research is the management of "Variants of Uncertain Significance" (VUS). In the world of clinical genetics, a VUS is a double-edged sword. It is a genetic alteration identified through sequencing, but one for which there is insufficient evidence to classify it as either pathogenic (disease-causing) or benign.
"While exome sequencing can be useful in identifying pathogenic or likely pathogenic variants in conditions with a genetic etiology, VUS may also be detected," Dr. Roman notes. "These VUS can be challenging to interpret in the context of limited data, such as phenotype or functional data, and this highlights the importance of periodically evaluating emerging data to potentially reclassify variants."
The NCGENES 2 study emphasizes that the work of a geneticist does not end when a report is generated. It is an iterative process. As scientific knowledge expands and more patients are sequenced, previously unknown variants are re-evaluated. This "reclassification" represents a critical bridge in the diagnostic odyssey, turning a "maybe" into a "yes" for patients long after their initial testing session.
Implications for the Human Genetics Community
The implications of the NCGENES 2 findings are twofold: they offer a potential roadmap for healthcare systems to optimize clinical resources, and they provide a necessary critique of current testing paradigms.
1. Clinical Efficiency
By demonstrating that early exome sequencing is feasible and potentially superior to tiered testing, the study suggests that healthcare providers could save both time and money. Rather than ordering a series of non-informative tests, a single, comprehensive diagnostic tool used early in the outpatient evaluation could streamline the path to treatment.
2. A Shift in Patient Care
The study highlights the human element of precision medicine. By engaging a multidisciplinary team, the project demonstrated that genomic data is most effective when interpreted through a lens that combines laboratory rigor with clinical expertise. For the patient, this means fewer repeat visits, less uncertainty, and a quicker start to appropriate therapeutic management.
Challenges for the Next Generation of Scientists
As a young scientist in a rapidly evolving field, Dr. Roman identifies the sheer pace of innovation as both a boon and a burden. The exponential increase in data volume and the continuous emergence of novel technologies—such as long-read sequencing and sophisticated AI-driven variant callers—create a "knowledge maintenance" challenge.
"The field of genetics is rapidly evolving," Dr. Roman explains. "It can be challenging to stay updated and familiar with novel technologies and increased data." This underscores the need for continuous education and adaptive research frameworks that allow scientists to remain agile as the technical landscape shifts beneath them.
Looking Forward: Frontiers in Genetics
When asked about what has caught her attention outside of her specific research project, Dr. Roman points to the intersection of genetic engineering and public health. She highlights the work of Dr. Kevin Esvelt and his group regarding heritable immunization in mice as a prime example of the power of modern genetics.
"One of the most fascinating topics is the research on heritable immunization in mice to control Lyme disease," she says. "In a recently published study, they used genetic engineering in mice to express a monoclonal antibody against Lyme-disease-causing bacteria, which was inherited across generations."
This interest reflects a broader trend in genomics: the movement from observing genetic patterns to actively manipulating them to solve large-scale ecological and health problems. While her clinical work focuses on diagnosing rare diseases, Dr. Roman’s fascination with this research demonstrates an appreciation for the vast, transformative potential of her field.
Conclusion
The work of Dr. Tamara Roman and the NCGENES 2 team provides a compelling argument for reassessing how we approach the diagnostic odyssey. By centering the patient experience and emphasizing the iterative nature of variant interpretation, the team has provided a blueprint for how clinical genetics can evolve to meet the needs of those waiting for answers.
As genetic sequencing becomes more accessible and the costs continue to drop, the challenge will shift from obtaining the data to interpreting it with speed and accuracy. If the findings from the NCGENES 2 study are any indication, the future of the field lies not just in the hardware of sequencing, but in the collaborative, multidisciplinary, and patient-centered framework that defines the best of modern clinical practice. The diagnostic odyssey may never be fully eliminated, but through the rigorous application of early, integrated exome sequencing, it can be significantly shortened—and for many families, that is the difference between a life of uncertainty and the beginning of a solution.
About the Author
